Abstract:There is no consensus for the treatment of recurrent rectal cancer. As FOLFOX has been the standard adjuvant chemotherapy, most recurrent patients have received oxaliplatin previously. This study is to investigate the local effect and toxicity of irinotecan and capecitabine concurrent with intensity-modulated radiation therapy in the treatment of recurrent rectal cancer. Fifty-eight patients (median age 53 years; m/f: 37:21) diagnosed with recurrent rectal cancer were treated in our hospital from October 2009 to November 2011. Eighty-two recurrent sites in all patients were included in which there were 27 cases with single site and 31 cases with multiple ones. Thirty-nine patients were confirmed recurrent rectal cancer without extra pelvic metastases while 19 patients with extra pelvic metastases. All patients underwent pelvic intensity-modulated radiation therapy of 45 Gy (1.8 Gy per fraction) followed by a boost of 10 Gy to 16 Gy (2 Gy per fraction) to the recurrent tumors. The concurrent chemotherapy regimen was irinotecan 50 mg/m2, weekly and capecitabine 625 mg/m2, bid (Mon-Fri.). Radical surgery was recommended if patients without extra pelvic metastases and the recurrent lesions were evaluated as resectable. The patients were follow-up every 3 months with clinical examinations, abdominal and pelvic CTs or MRIs. Tumor response was evaluated using CT/MRIs according to the RECIST criteria or postoperative pathological findings. NCI-CTC 3.0 was used to score the toxicities. The entire cohort included 82 recurrent sites, for the location of them, 30 sites were in peri-rectal region, 22 in pre-sacral region, 4 at external iliac nodal region, and 3 at inguinal nodal region. Eleven patients with locally recurrent rectal cancer underwent radical resections (R0) post chemoradiation. The pathologic complete response was observed in 7 of 11 patients. Clinical complete response was observed in 1 patient (1.7%) and partial response was 19 patients (32.8%). Only 4 patients showed progressive disease during or shortly after treatment. Of 41 symptomatic patients, clinical complete and partial symptom reliefs with chemoradiation were achieved in 56.1% and 36.6%. Only 2 patients experienced grade 4 leukopenia. The more common grade 3 toxicities were diarrhea (14 patients). In addition, grade 3 radiation dermatitis, leukopenia, and cystitis were observed in 5, 4, and 2 patients, respectively. This study showed irinotecan and capecitabine concurrent with intensity-modulated radiation therapy can relieved local symptoms significantly and exhibited promising efficacy with manageable toxicities in the recurrent rectal cancer. To improve the R0 resectable rate will be investigated in further study.

Phase Ii Study of Irinotecan and Capecitabine Concurrent with Intensity Modulated Radiation Therapy in the Treatment of Recurrent Rectal Cancer

Comparison of Two Different Neoadjuvant Chemoradiatiotherapy Regimens for Locally Advanced Rectal Cancer: Results of a Phase II, Multicenter, Randomized Trial.

Phase II Study of Neoadjuvant Short-Course Radiotherapy Combined with CAPEOX Plus Envafolimab in Patients with Microsatellite Stable Locally Advanced Rectal Cancer: Updated Results of PRECAM Study.

Long-course neoadjuvant chemoradiotherapy with versus without a concomitant boost in locally advanced rectal cancer: a randomized, multicenter, phase II trial (FDRT-002)

Three-dimensional Conformal Radiotherapy Combined with FOLFOX4 Chemotherapy for Unresectable Recurrent Rectal Cancer

CAPIRI-IMRT: a Phase II Study of Concurrent Capecitabine and Irinotecan with Intensity-Modulated Radiation Therapy for the Treatment of Recurrent Rectal Cancer

Efficacy of the radiotherapy combined with oxaliplatin and capecitabine in the treatment of local advanced rectal cancer

Phase Ii Trial Of Neoadjuvant Chemoradiation With Concomitant Boost Followed By A Coycle Of Xelox In Locally Advanced Rectal Cancer

Phase II Study of Computed Tomography-Guided (125)I-Seed Implantation Plus Chemotherapy for Locally Recurrent Rectal Cancer.

Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study

Accelerated Hyperfractionated Intensity-Modulated Radiotherapy for Recurrent/unresectable Rectal Cancer in Patients with Previous Pelvic Irradiation: Results of a Phase II Study

Compliance and Safety of Neoadjuvant Intensity Modulated Radiotherapy (imrt) with Concurrent Capecitabine for Locally Advanced Rectal Cancer: Updated Results from A Phase Ii Trial (Chictr-Tnc-10001094).

Postoperative Capecitabine With Concurrent Intensity-Modulated Radiotherapy Or Three-Dimensional Conformal Radiotherapy For Patients With Stage Ii And Iii Rectal Cancer

Toxicity Evaluation Of Capecitabine Concurrent Chemoradiotherapy For Stage Ii And Iii Rectal Cancer

Efficacy and Safety of Neoadjuvant Intensity-Modulated Radiotherapy with Concurrent Capecitabine for Locally Advanced Rectal Cancer

Multicentre Randomised Phase III Trial of Capecitabine with or Without Irinotecan Guided by UGT1A1 Status in Patients Undergoing Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer

A Phase Ii Study of Irinotecan and Capecitabine for Patients with Unresectable Liver-Only Metastases from Colorectal Cancer

Abstract CT090: Neoadjuvant Chemotherapy of FOLFIRI with or Without Radiotherapy in the Treatment of Marginally Resectable Recurrent Rectal Cancer Exposed to Oxaliplatin: A Cohort Study

A Randomized Multicentre Study of Chemoradiotherapy in Patients with Locally Advanced (inoperable) Rectal Cancer

Efficacy of Preoperative Neoadjuvant Simultaneous Integrated Boost IMRT Radiation Therapy Combined with Preoperative Chemotherapy for Locally Advanced Rectal Cancer: A Prospective II Clinical Study

Efficacy and Safety of Radiotherapy Combined with Raltitrexed and Irinotecan for Treating Unresectable Recurrent Colorectal Cancer: a Single-Arm Phase II Trial